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Introduction
Endoscopic ultrasound -guided fine-needle aspiration (EUS-
FNA) has for many years been recommended when evaluating
mass lesions of the pancreas where microscopic analysis was
deemed necessary for a clear-cut diagnosis [1]. FNA allows
evaluation of cytological features suggestive or diagnostic of
malignancy with high sensitivity and specificity, and the diag-
nostic accuracy is even higher when an on-site pathologist is
present to evaluate the quality of the obtained material [2–5].
However, due to lack of resources, this scenario is not possible
in many centers [3, 4]. FNAs are also faced with other problems.
Chronic pancreatitis can cause atypical cellular changes making
the distinction from well-differentiated neoplasia based solely
on cytological criteria difficult. In such difficult cases, the pos-
sibility to cut additional sections from a formalin-fixed and par-
affin embedded tissue block with application of immunohisto-
chemical markers may increase the diagnostic accuracy. More-
over, some entities such as mesenchymal tumors, autoimmune
pancreatitis (AIP), lymphoma [6] and a few rare pancreatic pri-
mary tumors are difficult to assess by FNA. Such lesions are
therefore better analyzed based on EUS-guided fine needle
biopsies (FNB) or tissue fragments obtained by EUS-FNA also
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ABSTRACT
Background and study aim Due to the scarcity of specific
data on endoscopic ultrasound (EUS)-guided fine-needle
biopsies (SharkCore) FNB in the evaluation of pancreatic le-
sions, we performed a prospective study of the diagnostic
performance of EUS SharkCore FNB in patients with pancre-
atic lesions. The aim of this study was to evaluate the diag-
nostic accuracy.
Patients and methods Single-center prospective study of
41 consecutive patients referred for EUS-FNB from October
2015 to April 2016 at our center. EUS-FNB was obtained in a
predefined setting regarding the procedure and pathologi-
cal evaluation. Data regarding demographics, lesion, tech-
nical parameters, and diagnostic accuracy were obtained.
Results The study included 41 consecutive patients (22
males (54%); median age 68 years). The average size of
the lesions was 28mm (median: 30mm). A diagnostic spe-
cimen was identified in 40 (98%) cases during microscopy
with an average of 2.4 passes. The route was trans-duode-
nal in 20 cases (49%). The histological diagnosis of the spe-
cimens was malignant in 29 cases (71%), benign in 8 (20%),
suspicious in 2 (5%), atypical in 1 (2%) and in 1 (2%) no ma-
terial for microscopic evaluation was obtained. This led to a
diagnostic accuracy of 93%, sensitivity of 91% and a speci-
ficity of 100%. 2 cases (5%) of self-limiting bleeding were
observed. The diagnosis at follow up was malignant in 32
(78%) of the patients.
Conclusions EUS-FNB of pancreatic mass lesions with the
SharkCore needle produced specimens with a diagnostic
accuracy of 93%. The procedure was safe and easy to per-
form, and these data support the use of EUS-FNB in a rou-
tine setting.
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making it possible to perform molecular and genetic analyses
for personalized treatment [7–9].
Since 2002 it has been possible to perform core biopsy guid-
ed by EUS using the so-called Quick-Core needle (Cook Endos-
copy Inc, Limerick, Ireland), and more recently the ProCore
needle from the same manufacturer has been evaluated [10,
11]. Currently, there is no standard regarding needle type,
size, or biopsy technique when performing pancreatic EUS-
FNB. A recently published meta-analysis comparing ProCore
FNB and standard FNA did not demonstrate a significant differ-
ence regarding sample adequacy, accuracy or acquisition of
histological material for evaluation. The ProCore needle, how-
ever, established the diagnosis with significant fewer passes
[12]. Experience with a novel FNB needle (SharkCore FNB nee-
dle, Medtronic, Dublin, Ireland) demonstrated excellent patho-
logic diagnostic performance also with a minimum of passes
[13, 14].
Due to the lack of specific data on EUS SharkCore FNB in the
evaluation of pancreatic lesions, we performed a prospective
study of the diagnostic performance of EUS SharkCore FNB in
patients with pancreatic mass-forming lesions. The aim of this
study was to evaluate the diagnostic accuracy of the needle.
EUS-FNB was only performed if it would have impact on the
treatment strategy [15].
Patients and methods
Patients referred for EUS-FNB from October 1, 2015 to April 30,
2016 were included in this consecutive and prospective single-
center trial, until 40 patients had histological or sufficient cyto-
logical material for microscopic evaluation. The center is a
high-volume center performing around 1000 EUS procedures
including 350 tissues samples a year (combination of FNA and
FNB). All the participating endoscopists were experienced and
had performed more than 150 procedures including tissue
sampling prior to start of this study. Inclusion criteria were
presence of a solid pancreatic mass on computed tomography
(CT) and/or magnetic resonance imaging and/or EUS, clinical
need for an exact diagnosis, age >18 years, and ability to pro-
vide informed consent. After EUS-FNB the final diagnosis (be-
nign/malignant) was established using 1 of the following meth-
ods: (1) definite proof of malignancy on a surgical specimen or
biopsy of a metastatic lesion; (2) malignant diagnosis on EUS-
FNB and clinical/imaging follow-up compatible with malignant
disease; or (3) no proof of malignancy on neither EUS-FNB nor
during clinical/imaging follow-up for at least 6 months. Patients
with a resectable mass on EUS and/or CT went directly for sur-
gery. This study concerns patients with a suspected but doubt-
ful or non-resectable mass. Non-resectable masses were biop-
sied for final diagnosis before oncological treatment. Complica-
tions were identified by retrospective review of the electronic
health records after at least 6 months both in house and in the
referring hospitals.
The study was approved by The Regional Committees on
Health Research Ethics for Southern Denmark and registered
in the ClinicalTrial.gov database (NCT03016637). Written and
informed consent was obtained from all enrolled patients.
EUS-FNB
EUS-FNB was only performed if the result would have impact on
the treatment strategy, i. e. if there was a clinical need for an ex-
act diagnosis of the histological type of pancreatic mass lesion.
EUS-FNB was performed using the SharkCore needle, guided by
a convex array echo-endoscope (Pentax EG-3870UTK; Pentax
Europe, GmbH, Hamburg, Germany). The endoscopist decided
whether to use the 25-G or the 22-G needle, and the pancreatic
mass lesion was punctured using the trans-duodenal or trans-
gastric approach. Prior to puncturing the target lesion, the sty-
let was retracted a few millimeters, and the tip of the needle
was advanced into the target tissue under endosonographic
guidance. The stylet was then retracted, while multiple move-
ments of the needle within the lesion were performed (slow
pull technique) [16]. If the second pass did not result in macro-
scopically visible core fragments as judged by the endoscopist,
suction was applied. Suction was released before removal of the
needle from the target. 1 to 3 needle passes were performed.
Tissue was recovered in formalin by pushing air and eventually
the stylet through the needle. All samples were processed at
the Department of Pathology, Odense University Hospital
(OUH). No pathologist was present in the endoscopy room.
Specimen preparation and evaluation
The SharkCore biopsies were fixed in formalin (6–24 hours) end
embedded in paraffin. Thirteen serial sections were cut from
the paraffin embedded tissue blocks. Section no. 1 and 13
were stained with hematoxylin & eosin (H&E), while section
no. 2 was stained with Alcian blue periodic acid-Schiff (AbPAS
pH 2.7). Sections 3–12 were initially left unstained. If neces-
sary for the final diagnosis, some of these sections were immu-
nohistochemically stained for markers such as CD56, monoclo-
nal CEA, chromogranin A, CK7, CK8, CK20, IMP3, Ki67, maspin,
S100P, SMAD4, synaptophysin or VHL. Additional markers were
used when necessary. All cases were evaluated and signed out
by 1 of 4 pathologists specialized in gastrointestinal pathology.
Statistics
Continuous data are presented with mean and standard devia-
tion. Results of diagnostic tests are reported with 95% confi-
dence intervals. Stata v. 12 (StataCorp, USA) was used.
Results
The study included 41 consecutive patients, 22 males (54%)
and 19 females (46%), with an average age of 68 years (range
36–88). 91% of the patients were in WHO performance status
0–1. 40 patients (98%) had a CT performed prior to EUS evalu-
ation and EUS-FNB (▶Table1). The final diagnosis was malig-
nant in 32 (78%) patients.
EUS-FNB procedure
7 endosonographers performed the 41 EUS-FNBs included in
this study. The 22-G needle was used in 38 (93%) cases and
the 25 G needle in 3 (7%). An average of 2.4 passes was used
(range 1–3), and the biopsies were obtained by the slow pull-
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technique in 39 (95%) cases. The average size of the pancreatic
lesions was 28±11mm (median: 30mm). The access route was
trans-duodenal in 20 cases (49%) and trans-gastric in 21 (51%)
cases. 2 cases (5%) of self-limited bleeding were observed dur-
ing the biopsy procedure, but none of the patients required ad-
ditional treatment or follow-up. There were not registered any
additional complications requiring contact to our institution or
the referring hospital. The endosonographers identified and
documented tissue cores or fragments in all patients.
Microscopic evaluation of the EUS-FNBs
A diagnostic specimen was identified in 40 (98%) cases during
microscopy, and the quality of the obtained biopsy was consid-
ered “good” in 39 (95%) cases. Details of the microscopic ex-
amination are shown in ▶Table2. Immunohistochemistry was
used in 38 (93%) of the cases as a supplement to H&E and Ab-
PAS.Histological diagnosis of EUS-FNB specimens was malig-
nant in 29 cases (71%) and benign in 8 cases (20%). 2 (5%) spe-
cimens were considered suspicious of malignancy, whereas 1
only consisted of a cytological smear of atypical cells (2%) and
another (2%) contained several blood cylinders but no material
relevant for microscopic evaluation. Among the malignant tu-
mors, 90% were classified as ductal adenocarcinomas of the
pancreas (▶Fig.1a and ▶Fig.1b) and the remaining 10% as
neuroendocrine tumors (NETs) (▶Fig. 1c and ▶Fig. 1d). 3 spe-
cimens were indicative of an intraductal-papillary mucinous
neoplasm (IPMN) (▶Fig. 1e and ▶Fig. 1f). 1 of the IPMN cases
was also suspicious of malignancy (▶Table 2).
Follow-up
None of the cases with a benign histological diagnosis turned
out to be malignant after at least 6 months of follow-up with
clinical evaluation and imaging. The patient with atypical cells
had a histologically confirmed malignant tumor, detected at
follow-up by laparoscopic ultrasound (LUS) guided core needle
biopsy. Of the 2 patients in whom malignancy was suspected, 1
had a malignant tumor diagnosed by a second SharkCore biop-
sy. In the calculation of the sensitivity, only conclusive malig-
nant histological diagnoses were considered malignant,
whereas cases specified as “atypical cells” and “suspicious of
malignancy” were considered benign. This led to a sensitivity
of 91% and a specificity of 100%, and an overall accuracy of
93% (▶Table3). There were no false-positive and 3 (7%) false-
▶ Table 2 Histological evaluation of EUS-FNB.
Quality of specimen as assessed by the pathologist (n = 41)
Good 39 (95%)
Poor 1 (2%)
No diagnostically useful specimen obtained 1 (2%)
FNB histological diagnosis
Malignant 29 (71%)
▪ Adenocarcinoma 26 (90%)
▪ NET 3 (10%)
Suspicion of malignancy 2 (5%)
▪ IPMN 1 (50%)
▪ High-grade dysplasia 1 (50%)
Atypical cells 1 (2%)
▪ Fibrosis 1 (100%)
Benign 8 (20%)
▪ Pancreatitis 2 (25%)
▪ Fibrosis 2 (25%)
▪ IPMN 2 (25%)
▪ Suspicion of leiomyomatous tumor 1 (12.5%)
▪ Normal tissue 1 (12.5%)
No diagnostically specimen obtained (blood cylinders) 1 (2%)
Gold standard / final histologic diagnosis
Adenocarcinoma 29 (71%)
NET 3 (7%)
Benign lesion 9 (22%)
FNB, fine-need biopsy; IPMN, intraductal papillary mucinous neoplasm; NET,
neuroendocrine tumor
▶ Table 1 Clinical data on 41 EUS-FNB patients.
Gender
Female 19 (46%)
Male 22 (54%)
Age
Average 68±11 years
Range 36–88 years
WHO Performance Status
0 13 (32%)
1 24 (59%)
2 3 (7%)
3 1 (2%)
Diagnostic workup before EUS-FNB
CT 40 (98%)
PET-CT 2 (5%)
ERCP 5 (12%)
Final diagnosis
Malignant 32 (78%)
Benign 9 (22%)
Final diagnosis based on
Histology– FNB 30 (73%)
Histology– Surgery 7 (17%)
Follow-up 4 (10%)
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negative specimens observed in this study. The overall correla-
tion between EUS-FNB and gold standard is shown in ▶Fig. 2.
Follow up for non-malignant cases is shown in ▶Table 4.
Discussion
EUS plays a central role in evaluation of pancreatic masses, and
if cytological proof of malignancy is clinically relevant for opti-
mal decision-making, cytological specimens can be obtained
using EUS-FNA. Test performance of standard EUS-FNA needles
has been evaluated in several prospective studies on patients
with solid pancreatic mass lesions. A meta-analysis demon-
strated a pooled sensitivity for EUS-FNA of 86.8% (95% confi-
dence interval [CI], 85.5–87.9) and a pooled specificity of
95.8 % (95% CI, 94.6–96.7) [17]. Despite these data the diag-
▶ Fig. 1 Microscopic examples of EUS-guided SharkCore biopsies from the pancreas. a H&E and b IMP3 immunostaining of ductal adenocarci-
noma of the pancreas. c H&E and d insulin immunostaining of insulin-producing neuroendocrine tumor of the pancreas. e H&E and f MUC5AC
immunostaining of intraductal-papillary mucinous neoplasm (IPMN) with gastric-type epithelium, low-grade dysplasia.
▶ Table 3 Diagnostic accuracy of EUS-FNB using the Sharkcore needle.
Intention to treat–N=41
Sensitivity 0.91 (0.75 –0.98)
Specificity 1.00 (0.66 –1)
Positive predictive value 1.00 ( 0.88–1)
Negative predictive value 0.75 (0.43 –0.95)
Overall accuracy 93% (80 –98%)
(95% confidence intervals); EUS-FNB, endoscopic ultrasound-guided fine-
need biopsy
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nostic yield may vary significantly, and the EUS-FNA technique
and the reported data suffer from several limitations. Endoso-
nographer experience [18], institution volume, presence or ab-
sence of on-site pathologist [3–5, 19], number of passes and
needles used [20], cytological rating of indeterminate diagno-
ses [21], presence of concomitant chronic pancreatitis, and
success rates outside clinical trials are just a few of the relevant
issues.
To circumvent some of these problems, several attempts
have been undertaken to obtain EUS-FNB for histological analy-
ses. Initial efforts were directed toward using large-caliber
(18 G) needles [22], and the Quick-Core and the ProCore biopsy
needles demonstrated diagnostic accuracy ranging from 42%
to 90% [10, 12, 23, 24]. However, large-caliber needles may re-
duce maneuverability in the duodenum and increase the rate of
complications, and focus has turned towards EUS-FNB with 25G
and 22G needles. Preliminary retrospective data using the 25G
and 22G SharkCore FNB needles in pancreatic lesions provided
a pathological diagnostic yield of 86% to 95% with a mean
number of passes of only 2 [13, 14]. In addition, the SharkCore
needle seemed able to provide significantly larger histological
specimens than the standard EUS-FNA needle [25]. The report-
ed lower number of passes with EUS-FNB was in concordance
with a meta-analysis comparing standard FNA and ProCore
FNB [12]. However, the diagnostic yield was identical between
the standard FNA needle and the FNB needle, and a subset anal-
FNB histological 
conclusion
41 Patients with pancreatic mass lesion
Gold standard/
final histological 
diagnosis
n = 29 
Malignant
26 Carcinoma
3 NET
1 Carcinoma
7 IPMN
1 Carcinoma 2 Normal
3 IPMN
1 Fibrosis
1 Leiomyoma
1 Pancreatitis
1 Carcinoma
n = 2
Suspicion of 
malignancy
n = 1
Atypical cells
n = 8 
Benign
n = 1
No material
▶ Fig. 2 Flowchart of patients undergoing EUS-FNB for pancreatic mass lesions. Blue: FNB Histological conclusion. White: Gold standard (final
histological diagnosis/follow up)
▶ Table 4 Follow up of non-malignant cases plus number of procedures during the follow-up period of 6 months.
Patient number FNB EUS+Biopsy LUS+Biopsy CT Final
diagnosis
4 Benign (suspicion of leiomyomatous tumor) – + + Leiomyoma
5 Benign (IPMN with LGD) + + – ++ IPMN– LGD
6 Benign (pancreatitis) – – + Pancreatitis
13 Benign (pancreatitis) + + + Pancreatitis
15 Atypical (fibrosis) – + – Adenocarcinoma
16 Non-tissue (blood clots) + – – Adenocarcinoma
191 Benign (fibrosis) + – ++ PANIN-2
25 Suspicion of malignancy (HGD) + – – Adenocarcinoma
28 Benign (fibrosis) – – + Pancreatitis
34 Suspicion of malignancy (IPMN) + + – ++ PANIN
35 Benign (normal tissue) + (– biopsy) – ++ Normal pancreas
40 Benign (IPMN with LGD) + + – ++ IPMN– LGD
CT, computed tomography; EUS, endoscopic ultrasound; FNB, fine-needle biopsy; HGD, high-grade dysplasia; IPMN, intraductal papillary mucinous neoplasm; LGD,
low-grade dysplasia; LUS, laparoscopic ultrasound; PAN IN, pancreatic intraepithelial neoplasia
1 The surveillance was stopped after 3 months due to severer psychiatric disease.
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ysis of pancreatic biopsies from a recent randomized study
were unable to detect any differences in the cellularity yield,
mean number of passes and reported adverse events [26].
Both EUS-FNA and FNB may sometimes fail to provide suffi-
cient material to establish the final diagnosis. Studies suggest
that EUS re-biopsy in patients with previous non-diagnostic
EUS-FNA from pancreatic lesions will lead to higher accuracy
rates [27], but this also means additional EUS investigations
and use of needles, increasing the costs. Therefore, any new
EUS-FNB needle should be monitored (and preferably tested
against standard EUS-FNA needles in a randomized trial) re-
garding manoeuvrability, tumor access, diagnostic accuracy,
number of passes, safety profile and overall costs until a final
diagnosis is reached.
Using the SharkCore needle in a prospective setting, we ob-
tained tissue suitable for microscopic analysis in the majority of
cases (98%), and the overall diagnostic accuracy for evaluating
pancreatic tumors was 93%. A similar high diagnostic yield of
86% to 95% and 87% for pancreatic lesions has been published
using the SharkCore needle and the ProCore needle, respective-
ly in retrospective studies [12–14]. An interesting finding in
the present study was the high proportion (49%) of FNB proce-
dures being performed through the duodenum with the endo-
scope in a J-flexed position. We experienced no needle handling
problems in this position. The 25-G needle was used in only 3
early cases (1 through the stomach), and after these initial ex-
periences the 22 G was chosen as standard for all EUS-FNB pro-
cedures. The needle flexibility and the trans-duodenal access
have been reported as limitations especially with the Quick-
Core needle [11, 23] but also with the ProCore needle, where
resistance to removing the stylet was hard in 18% and removal
impossible in 2% [10]. We experienced no problems related to
the use or removal of the stylet from the SharkCore needle in
any position, but difficulty in puncturing the target was report-
ed in 1 case. However, sufficient histological material was ob-
tained from this lesion, leading to suspicion of a leiomyoma. In
all samples a visible core was identified by the endosonogra-
pher. However, the inadequate sample consisted of several
blood cylinders at microscopy. To optimize macroscopic evalu-
ation of the specimens, we have tried photo documentation
and macroscopic measuring of the tissue cores. None of the
measures mentioned had a convincing effect.
A randomized study has shown the superiority of the fanning
technique compared to the standard technique during EUS-
FNA of solid pancreatic mass lesions [28]. It is easy to apply
the same technique with the SharkCore needle, but there are
no such data regarding this needle and it was not specifically in-
vestigated in the present study. A mean of 2.4 passes were per-
formed until a macroscopic specimen was obtained as judged
by the endoscopist, and this correlated with a diagnostically
conclusive biopsy specimen for microscopic evaluation in 95%
of the cases. 1 specimen (2.5%) contained only cytological ma-
terial and 1 (2.5%) only blood without any relevant tissue for a-
nalysis. Studies evaluating the diagnostic accuracy of the
SharkCore needle have reported a higher diagnostic accuracy
when comparing histological to cytological material, and in
both studies a histological biopsy was obtained with a median
number of 2 needle passes [13, 14]. However, the potential
clinical relevance of a low number of needle passes (i. e. regard-
ing the rate of complications) is unknown.
We experienced no complications apart from 2 small self-
limited bleeds during the procedure, which were asymptomat-
ic. In the only other study reporting on EUS SharkCore FNB-
related complications, a mild pancreatitis was reported in
2.9%. This is slightly higher than expected since a systematic re-
view found procedure-related pancreatitis in 0.4% at pancreat-
ic EUS-FNA [29]. However, larger prospective studies are need-
ed to establish the true risk profile of the SharkCore needle.
Thus, EUS-guided biopsy plays a significant role in up to one-
third of patients suspected of having pancreatic cancer, and the
actual clinical impact of EUS-guided biopsy will probably in-
crease, as more (rare) pancreatic diseases may be detected
when EUS-FNA and EUS-FNB are used more frequently [15].
Based on these first prospective data, EUS-guided SharkCore
biopsy may provide more material for pathological evaluation
and thus make a substantial contribution to the area of minimal
invasive diagnostics.
There are several limitations to this single-center non-com-
parative trial, and the results may not reflect practices or tech-
nologies used at other institutions. The relatively high number
of malignant tumors included may have biased the results. An-
other critical point in the present study is the use and definition
of the criterion-standard reference method. Ideally, when the
EUS-FNB was negative, histological confirmation based on sur-
gical specimens would be the criterion standard, but this can-
not be obtained for ethical reasons in this type of patients.
Therefore, clinical follow-up for at least 6 months with repeated
imaging procedures was used in these patients. Although not
ideal, this method is a well-accepted reference standard. 7 dif-
ferent endosonographers performed the biopsies, but we do
not consider this a true limitation, but rather a reflection of ev-
ery day routine in a large and busy endoscopic unit. In addition,
the lack of complications and technical problems may indicate
that the FNB needle is easy to use and without a learning curve.
Conclusion
In conclusion, EUS-FNB of pancreatic mass lesions with the
SharkCore needle produced specimens with a diagnostic accu-
racy of 93%. The procedure was safe and easy to perform, and
these preliminary data support the use of EUS-FNB in a routine
setting where establishing the histological type of pancreatic
tumors is clinically relevant. Future prospective and compara-
tive studies should focus on safety, diagnostic accuracy and
costs.
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